GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway

This publication has 25 references indexed in Scilit:

• Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
  The Lancet Oncology, 2015
• High-risk prostate cancer—classification and therapy
  Nature Reviews Clinical Oncology, 2014
• Increased Migration of Human Mesenchymal Stromal Cells by Autocrine Motility Factor (AMF) Resulted in Enhanced Recruitment towards Hepatocellular Carcinoma
  PLOS ONE, 2014
• Nerve Growth Factor in Cancer Cell Death and Survival
  Cancers, 2011
• Proteomic Identification of Paclitaxel-Resistance Associated hnRNP A2 and GDI 2 Proteins in Human Ovarian Cancer Cells
  Journal of Proteome Research, 2010
• 3,3′-Diindolylmethane Induction of p75NTR-Dependent Cell Death via the p38 Mitogen-Activated Protein Kinase Pathway in Prostate Cancer Cells
  Cancer Prevention Research, 2009
• Hsp90 Co-localizes with Rab-GDI-1 and Regulates Agonist-induced Amylase Release in AR42J Cells
  Cellular Physiology and Biochemistry, 2009
• Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers
  Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2007
• Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells
  Clinical & Experimental Metastasis, 1999
• Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor–induced cell growth by activation of programmed cell death
  Molecular Carcinogenesis, 1998